Shahin Najar-Peerayeh Selected Research

Shahin Najar-Peerayeh Research Topics

4	Cross Infection (Nosocomial Infection) 01/2021 - 08/2014
3	Infections 10/2022 - 02/2020
3	Hemolysis 01/2022 - 01/2019
3	Cholera 01/2020 - 11/2017
1	Inflammation (Inflammations) 11/2021
1	Septic Shock (Toxic Shock Syndrome) 11/2021
1	Necrosis 04/2021
1	Wound Infection (Wound Infections) 01/2020
1	Wounds and Injuries (Trauma) 01/2020
1	Burns 01/2020
1	Diarrhea 09/2016
1	Persistent Infection 10/2006

4	Anti-Bacterial Agents (Antibiotics)IBA 10/2021 - 01/2019
2	Vancomycin FDA LinkGeneric 01/2021 - 12/2018
2	VaccinesIBA 01/2020 - 10/2006
2	SeleniumIBA 01/2020 - 01/2020
1	Carbapenems (Carbapenem Antibiotics)IBA 10/2022
1	Hemolysin Proteins (Hemolysins)IBA 01/2022
1	AgarIBA 01/2022
1	AntibodiesIBA 11/2021
1	LipopolysaccharidesIBA 11/2021
1	Panton-Valentine leukocidinIBA 04/2021
1	Anti-Infective Agents (Microbicides)IBA 02/2020
1	Silicon Dioxide (Silica)FDA LinkGeneric 01/2020
1	Mupirocin (Bactroban)FDA LinkGeneric 01/2020
1	Naloxone (Narcan)FDA LinkGeneric 01/2020
1	Narcotic Antagonists (Opioid Antagonists)IBA 01/2020
1	Clindamycin (Cleocin)FDA LinkGeneric 01/2020
1	ChitosanIBA 01/2020
1	Therapeutic UsesIBA 01/2020
1	ExotoxinsIBA 08/2019
1	Cholera ToxinIBA 11/2017
1	FlagellinIBA 09/2016
1	CoagulaseIBA 08/2014
1	AlginatesIBA 10/2006

1	Therapeutics 10/2022